课题基金 / 基金详情

Pharmacologic and RNAi Screens for Myotonic Dystrophy Type 1 foci modulators; towards Novel DM1 therapeutic approaches

Pharmacologic and RNAi Screens for Myotonic Dystrophy Type 1 foci modulators; towards Novel DM1 therapeutic approaches
强直性肌营养不良 1 型病灶调节剂的药理学和 RNAi 筛选；
批准号：
381224
负责人：
Mackenzie Alexander E
金额：
$35.11万
依托单位：
Children's Hospital of Eastern Ontario- Ottawa Children's Treatment Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-03-01 至 2021-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=381224&lang=en
关键词：
Cell Phenotype Drug Screen Muscular Dystrophy

项目摘要

项目成果

Mackenzie Alexander E的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Myotonic Dystrophy Type 1 (DM1) is the most common form of adult muscular dystrophy affecting as many as 1 in 500 people in some regions of Quebec. DM1 can manifest in infancy, in old age or at any stage in between affecting all systems in the body inclu
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Recognition and Validation of Druggable Targets from the Response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from Integrated -Omics Networks
  • 批准号：
    387442
  • 项目类别：
    Operating Grants
  • 资助金额：
    $5.46万
  • 财政年份：
    2018
  • 负责人：
    Mackenzie Alexander E
  • 依托单位：
    University of Ottawa
Preclinical assessment of clinic ready agents for the treatment of muscular dystrophy and spinal muscular atrophy
海外基金